The 2026 Oncology Nursing Society (ONS) Congress is set for May 13 through May 17 in San Antonio, Texas. The 51st Annual ONS Congress features five days of networking, research presentations, and educational opportunities dedicated advancing the field of oncology nursing. 

At the 2026 ONS Congress, attendees will learn from leading experts about the latest advancements in cancer care delivery and symptom management across a spectrum of session types and topics. Today, we are highlighting sessions focusing on or related to hematology/transplant/cellular therapy topics. For a look at the full schedule, visit the 2026 ONS Congress program for the most thorough look at the following sessions and more. 

Hematology/Transplant/Cellular Therapy Sessions at ONS Congress 2026
Thursday, May 14

Implementing CAR T-cell and BiTE™ Therapies Ideas Exchange

  • 2:00 PM – 2:50 PM
  • Description: During this networking session, attendees can discuss experiences and success strategies with colleagues who are navigating the complexities of CAR-T and BiTE therapies at their institutions.

Target. Engage. Destroy: The BiTE™ Revolution in Cancer Treatment

  • 3:00 PM – 4:00 PM
  • Description: Gain clinical insights into managing patients receiving bispecific antibodies with a focus on the importance of interdisciplinary collaboration. Speakers will address recognizing, preventing, and managing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

Project Presentations: Stem Cell Transplant

  • 4:15 PM – 5:15 PM
  • Description: In this oral abstract presentation session, abstract authors present their projects that improved patient care and processes. Abstracts include: Integration of a Virtual Nurse on a Inpatient Bone Marrow Transplant Unit, Symptom Profiles and Associated Biopsychosocial Risk Factors during Pediatric Cellular Therapy: A Secondary Analysis, Establishing a Collaborative Survivorship Clinic Model for Allogeneic Transplant Patients, and more.
Friday, May 15

What to Know About Long-Term Endocrine Toxicities of Checkpoint Inhibitors

  • 10:00 AM – 11:00 AM
  • Description: Patients are living longer after cancer, and many experience long-term effects of treatment well beyond the discharge from an oncologist’s care. Learn how to educate patients to be prepared for these effects, which can present early and last for the rest of their lives.

Adherence, Cost, and Combination Therapy: Addressing Oral Anticancer Agent Management Issues

  • 3:00 PM – 4:00 PM
  • Description: The increase in available oral anticancer agents gives patients more options for treatment, while presenting both benefits and barriers. Take a closer look at the benefits, like fewer visits to the cancer center, and the barriers, like cost, adherence, and complexity of care, particularly for patients receiving combined oral and IV therapies.

Project Presentations: Bispecific and Cellular Therapy Readiness

  • 4:15 PM – 5:15 PM
  • Description: In this oral abstract presentation session, abstract authors present their projects that improved patient care and processes. Abstracts include: Implementation and Standardization of Outpatient Bispecific High Risk Immunotherapy Regimens, From Vague to Vital: Nurse-Led Flowsheet Innovation Standardizing Cerebellar Neurotoxicity Assessment, and more.
Saturday, May 16

Project Presentations: Vascular Access Devices

  • 10:00 AM – 11:00 AM
  • Description: In this oral abstract presentation session, abstract authors present their projects that improved patient care and processes. Abstracts include: From Evidence to Impact: Transforming Venous Access Device Outcomes Through EBP, Stopping the Bleed, STAT: Using Statseal for Cellular Therapy Patients, and more.

Showcasing the New ONS/ASCO Extravasation Treatment Guidelines: An Expert-Led Session

  • 3:00 PM – 4:00 PM
  • Description: Direct care nurses will have the unique opportunity to learn directly from the authors of the latest extravasation treatment guidelines. These comprehensive guidelines were developed by a panel of renowned oncologists and oncology nursing experts, providing the definitive best practices for managing this critical patient safety issue.
Sunday, May 17

The Latest FDA Approvals and Their Clinical Applications

  • 9:15 AM – 10:45 AM
  • Description: This session will discuss the new cancer drugs that the U.S. Food and Drug Administration approved within the past year. Attendees will be introduced to these novel treatments and identify evidence-based interventions for managing treatments and side effects.

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.